Commercial sparring for medtech innovators navigating China
For overseas and China-based medtech innovators making critical China commercialization decisions, MediVantage helps clarify where to start, what to validate, and how to make the commercial path credible.
Three focused decision packages for medtech commercialization
Each package is short, practical, and built around a decision clients need to make now. AI accelerates the work; founder-led commercial judgment shapes the answer.
China Opportunity Snapshot
A fast view on which China opportunity is most realistic, where to focus first, and what assumptions need testing.
First Commercialization Blueprint
A practical first-step commercialization plan for overseas or China-based innovators with promising products and limited commercial infrastructure.
Commercialization Readiness Check
An honest read on whether your product is ready for investor diligence, partner talks, or an internal go decision — and what to close before it is.
Focused commercial judgment for the decision in front of you
Clinical and commercial lens connects product and clinical realities to adoption, pricing, channel, and access decisions.
China execution context grounded in hospitals, channels, pricing, market access, and domestic competition.
Cross-border translation turns China market realities into choices overseas and China-based teams can act on.
Large strategy consulting
Enterprise strategy, transformation, and multi-workstream programs for broader, larger-scale questions.
MediVantage
Founder-led judgment focused on one commercialization decision and the next practical move.
Data & market intelligence
Market sizing, survey data, and syndicated research—strong on evidence, not decision ownership.
Regulatory & market access
NMPA, clinical, regulatory, reimbursement, and access pathway support.
MediVantage sits between market evidence and commercial execution, helping innovation teams decide what to do next before committing resources.
Every sprint starts with the decision, then works backward to the evidence
Frame the decision
Clarify what the team must decide and what would change the answer.
Map the commercial reality
Use market signals, stakeholder input, competitor behavior, and frontline China knowledge.
Pressure-test assumptions
Separate attractive narratives from adoption, pricing, access, and channel reality.
Recommend next moves
Deliver the practical answer: focus, wait, validate, partner, launch, redesign, or refocus.
Product status, target indication, China assumptions, stakeholder questions, pricing and channel constraints.
Focused working sessions to test assumptions, resolve trade-offs, and align next-step decisions.
A practical decision view, evidence priorities, action sequence, and risks the team should continue watching.
Michael Wang
Clinical judgment, commercial execution, and China-global translation
With a background in Clinical Medicine, Michael brings nearly 20 years of healthcare commercial experience across global medtech and pharmaceutical companies. His deepest experience is in Neurovascular and Acute Therapies, with broader work spanning Laboratory Diagnostics, Renal Care, Biosurgery, Immunology, and hospital sales.
He combines hands-on commercial leadership in China with cross-border experience across APAC, global, and US teams. AI-augmented market intelligence helps him synthesize evidence faster, while the interpretation, commercial judgment, and recommendation remain founder-led and personally accountable.
He combines hands-on commercial leadership in China with cross-border experience across APAC, global, and US teams. AI-augmented market intelligence helps him synthesize evidence faster, while the interpretation, commercial judgment, and recommendation remain founder-led and personally accountable.
For medtech innovators and investors who need fast commercial judgment
Best suited for focused decisions where a team needs a credible commercial view before committing scarce time, capital, or operating resources.
Overseas growth-stage medtech companies evaluating China entry
Teams with promising products, limited China commercial infrastructure, and a need to decide where entry is realistic.
China-based medtech innovators preparing first commercialization
Local innovation teams that need practical judgment on first segment, pricing, evidence, channels, and early adoption.
Healthcare investors assessing commercialization risk
Investors evaluating whether a medtech product's China or commercialization story is credible, executable, and investable.
China entry question · unclear first segment · investor diligence · pricing uncertainty · limited commercial team · partner decision
Opportunity snapshot · first commercialization path · readiness scorecard and gap map
Need a clearer first commercialization path?
Bring the product, China question, investor concern, or partner discussion. We will help frame what needs to be decided and what assumptions should be tested next.
Opportunity prioritization, first commercialization path, pricing logic, evidence gaps, partner questions, investor diligence, or readiness gaps.
30 minutes, confidential, focused on the decision context rather than a generic sales presentation.
For email inquiries, include your product area, China status, and the decision you are trying to make.